Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years

Ghadiri, Fereshteh; Sahraian, Mohammad Ali; Baghbanian, Seyed Mohammad; Ashtari, Fereshteh; Razazian, Nazanin; Majdinasab, Nastaran; Poursadeghfard, Maryam; Hatamian, Hamidreza; Harirchian, Mohammad Hossein; Moghadam, Nahid Beladi; Azimi, Amirreza; Sharifipour, Ehsan; Hosseini, Samaneh; Bayat, Asghar; Kamali, Hoda; Mir, Nahid Hosseni Nejad; Faraji, Fardin; Mozhdehipanah, Hossein; Modara, Farhad; Navardi, Samira; Heidari, Hadi; Ayoubi, Saeideh; Moghadasi, Abdorreza Naser; Eskandarieh, Sharareh

doi:10.1016/j.msard.2022.103777

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10,24 The shifting trend from classical injectable DMTs to Group 2 oral DMTs aligns with previous studies. 13,14,25 The cause of this shift may include convenience of administration, better efficacy and the consideration of safety profile, dosage and medicine adherence. 8,26,27 However, there was a significant inter-state/territory variation on how long it took Group 2 DMTs to become more frequently prescribed than Group 1.…”

Section: Discussionmentioning

confidence: 99%

“…For example, the most common DMTs in the United States in 2019 were dimethyl fumarate, glatiramer acetate and fingolimod, 14 and the most common DMTs in Iran in 2020 were rituximab, glatiramer acetate and interferon beta-1a. 25 Within Australia, the popularity of individual DMTs varied between States/Territories. While the actual DMT usage reflects not only neurologist preferences for DMT characteristics but also patient preferences, prescription guidelines, reimbursement policies, DMT accessibility and marketing efforts, 28 it also could be a result of an absence of standard guidelines for decision-making regarding DMT selection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022

Zhao,

Taylor,

Campbell

et al. 2023

Mult Scler

View full text Add to dashboard Cite

Background: The MS disease-modifying therapies (DMTs) prescribing landscape in Australia have changed over time. Objectives: This study evaluated the utilisation and cost trends of MS-related DMTs in Australia over 10 years and investigated differences between States/Territories. Methods: The prescription and costs of 16 DMTs were extracted from the Pharmaceutical Benefits Scheme for 2013–2022. Descriptive approaches analysed the total number of people prescribed DMTs and total DMT costs per 10,000 population, proportions of prescriptions/costs by DMT groups and the number of people prescribed each individual DMT and costs of each DMT over the 10-year period. All estimates were for Australia and each State/Territory individually. Results: The number of people prescribed DMT and costs per 10,000 population had substantial growth between 2013 and 2022: 125%/164% for Australia, and 94%–251%/129%–373% for individual States/Territories. Higher efficacy group accounted for 54% of total people prescribed DMTs in 2013 and 75% in 2022. Fingolimod was the most popular DMT until 2020, then was dominated by ocrelizumab. The trends of individual DMT prescriptions and costs differed between states particularly in Western Australia (WA), Tasmania and Northern Territory (NT). Conclusion: DMT prescriptions and costs continuously increased over the last decade, particularly for higher efficacy DMTs, and their trends differed between States/Territories.

show abstract